IJPR  artciles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 1.55 (2012 - 2016). 

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

ISSN
0975-2366
5 - Years Impact Factor

Year 2012 - 2016

Impact Factor: 1.55

Total Publications: 317

Total Citation: 491

Year 2011 - 2015

Impact Factor: 1.46

Total Publications: 326

Total Citation: 477

Year 2010 - 2014

Impact Factor: 1.3

Total Publications: 313

Total Citation: 407

Year 2009 - 2013

Impact Factor: 0.973

Total Publications: 293

Total Citation: 285

Current Issue
22nd NATIONAL CONVENTION

22nd National Convention of Society of Pharmacognosy & International Conference. For more details visit


For More Detail Visit ncsp.ganpatuniversity.ac.in
Article In Press
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPRT ISSUE

January - March 6 [1] 2014

Click to download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
PIPPHARMACON & IJPR 2018

PIPPHARMACON & IJPR 2018

Click to download
 

Article Detail

Label
Label
A BRIEF REVIEW ON DIABETIC NEUROPATHY

Author: RASIKA NIKHADE, SUCHITA WAGHMARE, DR. SATISH KOSALGE
Abstract: Diabetic nephropathy is the leading cause of kidney disease in patients starting renal replacement therapy and affects 40% of type 1 and type 2 diabetic patients. It increases the risk of death, mainly from cardiovascular causes, and is defined by increased urinary albumin excretion (UAE) in the absence of other renal diseases. Diabetic neuropathy can be classified as peripheral, autonomic, proximal, or focal. A number of risk factors have been identified in the development of DN that include genetic susceptibility, elevated blood pressure, increased blood sugar, smoking and dyslipidemia. Moreover, various hyperglycemia-induced signaling mechanisms including increased formation of advanced glycation end products (AGEs), enhanced reactive oxygen species (ROS) generation and activation of protein kinase C (PKC). ACE inhibitors and angiotensin receptor blockers (ARBs) appeared to be successful in reducing the proteinuria and decreasing the creatinine doubling rate. These drugs decrease urinary albumin excretion (UAE) and the rate of progression from microalbuminuria to more advanced stages of DN and hence, the combination of these classes of drugs has been proposed as an alternative to treat DN. Replacing red meat with chicken in the usual diet reduced UAE by 46% and reduced total cholesterol, LDL cholesterol, and apolipoprotein B in microalbuminuric patients with type 2 diabetes in a 4-week study
Keyword: Diabetic nephropathy, urinary albumin excretion (UAE), ACE inhibitors.
Download: Request For Article
 












USER LOGIN


Username
Password
Login | Register
AICTE INTERNATIONAL CONFERENCE

AICTE Sponsored International Conference on Challenges, Opportunities and Newer Directions of Pharmacovigilance and Clinical Research in India

Download Brochure


For More Detail Visit www.pippharmacon.org
News & Events

CiteScore 2016 -  0.09

SJR 2016 - 0.111

SNIP 2016 - 0.055

Impact Factor for five years is 1.55 (2012 - 2016)
Year 2011 - 2015 Impact Factor - 1.46 Total Publications - 326 Total Citations - 477
Impact Factor for five years is 1.3 (2010 - 2014)